Implications of drugs with rebate in Europe

被引：30

作者：

Bonetti, Andrea ^{[1
]}

Giuliani, Jacopo ^{[1
]}

机构：

[1] Az ULSS 9 Scaligera, Dept Oncol, Via Gianella 1, I-37045 Legnago, VR, Italy

来源：

LANCET REGIONAL HEALTH-EUROPE | 2021年 / 3卷

关键词：

PRICE;

D O I：

10.1016/j.lanepe.2021.100060

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

引用

页数：2

共 9 条

[1]

Carl D.L., LANCET REG HEALTH-EU, V3, DOI [10.1016/j.lanepe.2021.100050, DOI 10.1016/J.LANEPE.2021.100050]

[2] The impact of managed entry agreements on pharmaceutical prices [J].

Gamba, Simona ;

Pertile, Paolo ;

Vogler, Sabine .

HEALTH ECONOMICS, 2020, 29 :47-62

[3] The cost of cancer in Europe 2018 [J].

Hofmarcher, Thomas ;

Lindgren, Peter ;

Wilking, Nils ;

Jonsson, Bengt .

EUROPEAN JOURNAL OF CANCER, 2020, 129 :41-49

[4] Innovation and drugs price and reimbursement: a comparison between Italy and the other major EU countries [J].

Jommi, Claudio .

GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2015, 2 (03) :117-124

[5] Payers' experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia [J].

Morgan, Steven G. ;

Vogler, Sabine ;

Wagner, Anita K. .

HEALTH POLICY, 2017, 121 (04) :354-362

[6] Managed Entry Agreements for Oncology Drugs: Lessons from the European Experience to Inform the Future [J].

Pauwels, Kim ;

Huys, Isabelle ;

Vogler, Sabine ;

Casteels, Minne ;

Simoens, Steven .

FRONTIERS IN PHARMACOLOGY, 2017, 8

[7] Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval [J].

Prasad, Vinay ;

Mailankody, Sham .

JAMA INTERNAL MEDICINE, 2017, 177 (11) :1569-1575

[8] The high price of anticancer drugs: origins, implications, barriers, solutions [J].

Prasad, Vinay ;

De Jesus, Kevin ;

Mailankody, Sham .

NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (06) :381-390

[9]

Vokinger KN, 2020, LANCET ONCOL, V21, P664, DOI 10.1016/S1470-2045(20)30139-X

← 1 →